PRINCETON, N.J., Nov. 15, 2017 /PRNewswire/ -- Promius Pharma LLC announced today that ZEMBRACE ® SymTouch ® (sumatriptan injection) 3 mg, an acute migraine headache treatment on the market since ...

Dr. Reddy's Laboratories (NYSE: RDY), announced today that the U.S. Food and Drug Administration (FDA) has approved ZEMBRACE™SymTouch™ (sumatriptan succinate) injection, a drug-device combination ...

Tosymra Nasal Spray 10 mg is a Proprietary Acute Migraine Treatment Approved Under the 505(b)2 Pathway Based on Bioequivalence to Imitrex (sumatriptan) Injection 4 mg GlaxoSmithKline Recently Notified ...

MUMBAI, Feb 17 (Reuters) - Drug firm Wockhardt Ltd on Tuesday said it will be launching Sumatriptan injections in the U.S. following following final approval from the U.S. Food & Drug Administration.

Sumatriptan 5mg, 20mg; per spray. The vascular 5-HT 1 receptor subtype to which sumatriptan binds selectively, and through which it presumably exerts its antimigrainous effect, is present on cranial ...

Par Pharmaceutical Companies, Inc. said today it will pay Spectrum Pharmaceuticals, Inc., $20 million for more profits from a collaboration to sell a copycat migraine drug.Par Pharmaceutical Companies ...

OTTAWA, ONTARIO -- (Marketwired) -- 11/01/13 -- The issue: GlaxoSmithKline Inc., in consultation with Health Canada, is voluntarily recalling two lots of "IMITREX Injection", a migraine medication ...

Imitrex is available as a generic drug. The maximum single recommended adult dose of Imitrex Injection for the acute treatment of migraine or cluster headache is 6 mg injected subcutaneously. For the ...

Strategic Acquisition Helps Build Tonix’s Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for the Management of Fibromyalgia Acquisition of Zembrace® SymTouch® ...

Nov 13 (Reuters) - Drugmaker Spectrum Pharmaceuticals Inc. on Monday said it settled a patent suit with GlaxoSmithKline relating to the UK-based company's migraine injection, Imitrex. Under the terms, ...

Chatham-based Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiary Tonix Medicines Inc. announced June 26 that they entered into an agreement to acquire two fast-acting migraine ...